# Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

> **NCT00297167** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 34 (actual)

## Conditions studied

- Cystic Fibrosis
- Exocrine Pancreatic Insufficiency

## Interventions

- **DRUG:** EUR-1008 (APT-1008)
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** EUR-1008 (APT-1008)

## Key facts

- **NCT ID:** NCT00297167
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00297167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00297167, "Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00297167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*